PURPOSE: To test whether citrate is elevated in adult patients with gliomas using (1)H magnetic resonance spectroscopy (MRS) at 3T in vivo. METHODS: Thirty-four adult patients were enrolled in the study, including six subjects with glioblastomas, eight subjects with astrocytomas (World Health Organization grade 3, n = 5; grade 2, n = 3), and 20 subjects with oligodendrogliomas (grade 3, n = 5; grade 2, n = 15). Five healthy volunteers were studied for baseline citrate data. Single-voxel localized spectra were collected with point-resolved spectroscopy (PRESS) echo times of 35 and 97 ms and were analyzed with LCModel software using numerically calculated basis spectra that included the effects of the PRESS radiofrequency and gradient pulses. RESULTS: Citrate was not measurable by MRS in healthy brain but was detected in tumor patients at both echo times. The citrate concentration was estimated to be as high as 1.8 mM with reference to water at 42 M, with Cramér-Rao lower bounds (CRLB) as low as 5%. The mean citrate level was 0.7 ± 0.4 mM (mean ± SD, n = 32) with a median CRLB of ∼12%. No correlation was identified between citrate concentration and tumor grade or histological type. CONCLUSION: Citrate was increased in the majority of gliomas in adult patients. The elevated citrate in our data indicates an altered metabolic state of tumor relative to healthy brain.
PURPOSE: To test whether citrate is elevated in adult patients with gliomas using (1)H magnetic resonance spectroscopy (MRS) at 3T in vivo. METHODS: Thirty-four adult patients were enrolled in the study, including six subjects with glioblastomas, eight subjects with astrocytomas (World Health Organization grade 3, n = 5; grade 2, n = 3), and 20 subjects with oligodendrogliomas (grade 3, n = 5; grade 2, n = 15). Five healthy volunteers were studied for baseline citrate data. Single-voxel localized spectra were collected with point-resolved spectroscopy (PRESS) echo times of 35 and 97 ms and were analyzed with LCModel software using numerically calculated basis spectra that included the effects of the PRESS radiofrequency and gradient pulses. RESULTS:Citrate was not measurable by MRS in healthy brain but was detected in tumorpatients at both echo times. The citrate concentration was estimated to be as high as 1.8 mM with reference to water at 42 M, with Cramér-Rao lower bounds (CRLB) as low as 5%. The mean citrate level was 0.7 ± 0.4 mM (mean ± SD, n = 32) with a median CRLB of ∼12%. No correlation was identified between citrate concentration and tumor grade or histological type. CONCLUSION:Citrate was increased in the majority of gliomas in adult patients. The elevated citrate in our data indicates an altered metabolic state of tumor relative to healthy brain.
Authors: Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer Journal: Radiology Date: 2011-10 Impact factor: 11.105
Authors: Changho Choi; Ivan E Dimitrov; Deborah Douglas; Aditya Patel; Lana G Kaiser; Carlos A Amezcua; Elizabeth A Maher Journal: NMR Biomed Date: 2010-11 Impact factor: 4.044
Authors: Stefan Blüml; Ashok Panigrahy; Mikhail Laskov; Girish Dhall; Mark D Krieger; Marvin D Nelson; Jonathan L Finlay; Floyd H Gilles Journal: Neuro Oncol Date: 2011-07-19 Impact factor: 12.300
Authors: Alan J Wright; Greg A Fellows; John R Griffiths; M Wilson; B Anthony Bell; Franklyn A Howe Journal: Mol Cancer Date: 2010-03-23 Impact factor: 27.401
Authors: Andrew R Mullen; William W Wheaton; Eunsook S Jin; Pei-Hsuan Chen; Lucas B Sullivan; Tzuling Cheng; Youfeng Yang; W Marston Linehan; Navdeep S Chandel; Ralph J DeBerardinis Journal: Nature Date: 2011-11-20 Impact factor: 69.504
Authors: Zhongxu An; Sandeep K Ganji; Vivek Tiwari; Marco C Pinho; Toral Patel; Samuel Barnett; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Changho Choi Journal: Magn Reson Med Date: 2016-07-25 Impact factor: 4.668